Rockwell Medical

Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini in January 1995 and is headquartered in Wixom, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Rockwell Medical reports record revenue and eyes global expansion

Rockwell Medical's Q4 2022 earnings call showcased strong revenue growth, operational improvements, and strategic initiatives for future profitability. While challenges in expense optimization and debt reduction persist, the company's focus on growth through international partnerships and new product developments presents promising opportunities. Overall, Rockwell Medical is on track to achieve financial stability and sustained growth in the healthcare market.

Rockwell Medical reports record revenue and progress towards profitability

Rockwell Medical (RMTI) delivered strong Q1 2023 results with record revenue and progress towards profitability. The company's strategic initiatives, including the successful transition of the Baxter business, are driving growth. Despite challenges, Rockwell Medical's focus on cost reduction and business development positions it well for future success.

Rockwell Medical reports Q2 challenges but eyes profitability in 2024

Rockwell Medical's Q2 2023 performance reflects challenges in net sales and profitability but highlights strategic progress towards financial stability and growth.
The company's strengths lie in revenue increase, expense reduction, and the acquisition of Evoqua's business, positioning it for accelerated profitability.
While facing challenges in financial results and product development, Rockwell's focus on market expansion and optimization presents opportunities for future growth and revenue diversification.

Rockwell Medical posts record Q3 sales, eyes profitability in Q4

Rockwell Medical's Q3 performance reflects strong sales growth and strategic acquisitions.
While facing margin challenges, the company's focus on profitability and leadership enhancements bode well.
Opportunities lie in market dominance, operational improvements, and leveraging customer agreements.
Maintaining financial stability and pursuing growth avenues are key priorities for Rockwell's future success.

Rockwell Medical achieves historic profitability and projects strong sales growth

Rockwell Medical's Q4 2023 performance reflects significant milestones with profitability achieved and record net sales reported. The company's strategic focus on operational efficiency, growth projections, and margin improvements indicate a positive trajectory. While challenges persist, Rockwell is well-positioned to leverage opportunities for sustained growth and profitability.

Rockwell Medical reports record Q1 sales and profitability growth

Rockwell Medical delivered robust financial results in Q1 2024, showcasing growth in net sales, gross profit, and improved profitability metrics.
The company's strategic initiatives to enhance margins, optimize operations, and reduce debt position it well for future growth and value creation.
While facing challenges in a competitive market, Rockwell's unique market position and financial discipline provide a solid foundation for sustained success.

Rockwell Medical reports record-high sales and profitability, eyes global expansion

Rockwell Medical's Q3 2024 performance reflects strong financial health, profitability, and record-high sales, underpinned by strategic initiatives and partnerships.
The company faces challenges in customer dynamics but is well-positioned to capitalize on growth opportunities in at-home dialysis and international markets.
With a focus on quality, customer service, and sustainable profitability, Rockwell Medical is poised for continued success and market expansion.
Overall, Rockwell Medical's Q3 2024 earnings call highlights resilience, adaptability, and a positive outlook for future growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini in 1996 and is headquartered in Wixom, MI.

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #Collaboration--Rockwell Medical entered into a three-year co-promotion services agreement with B. Braun Medical Inc.

Rockwell Medical Announces 3-Year Co-Promotional Collaboration with B. Braun Medical

Does Rockwell Medical (RMTI) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Rockwell Medical (RMTI) a Strong Momentum Stock: Buy Now?

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #RussellRecon--Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company was added to the Russell Microcap® Index. The newly reconstituted index took effect after the market close on Friday, June 23, 2023. Membership in the Russell Microcap® Index remains in place for one year and means automatic inc.

Rockwell Medical Added to Russell Microcap Index

Rockwell Medical (RMTI) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Despite Fast-paced Momentum, Rockwell Medical (RMTI) Is Still a Bargain Stock

Rockwell Medical stock is rated a strong buy due to its growth prospects, low valuation, and solid profitability compared to the sector. The company focuses on products used in hemodialysis treatment, with a large market potential and increasing revenues. Risks include dilution and cash burn rate, but the company is working on expanding revenues and cutting costs to reach profitability.

Rockwell Medical: Buy This Undervalued Growth Story

Rockwell Medical, Inc. (NASDAQ:RMTI ) Q1 2023 Earnings Conference Call May 15, 2023 8:00 AM ET Company Participants Heather Hunter - Senior Vice President and Chief Corporate Affairs Officer Mark Strobeck - President and Chief Executive Officer Paul McGarry - Senior Vice President, Finance and Chief Accounting Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Operator Good morning and welcome to Rockwell Medical's First Quarter 2023 Results Conference Call and Webcast. Please note this event is being recorded.

Rockwell Medical, Inc. (RMTI) Q1 2023 Earnings Call Transcript

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical (Nasdaq: RMTI) today announced financial and operational results for the three months ended March 31, 2023.

Rockwell Medical Announces First Quarter 2023 Results

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Rockwell Medical (RMTI) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Rockwell Medical (RMTI) Is Attractively Priced Despite Fast-paced Momentum

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Geographic expansion, domestically and internationally, is a major focus for Rockwell Medical as we work to achieve profitability in 2024.

Rockwell Medical Announces Global Expansion into the United Arab Emirates

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Drogsan Pharmaceuticals is making great strides in its plan to register and commercialize Triferic AVNU in Turkey.

Rockwell Medical's Partner Drogsan Pharmaceuticals Submits Marketing Authorization Application in Turkey for Triferic AVNU

Rockwell Medical (RMTI) Shows Fast-paced Momentum But Is Still a Bargain Stock

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its financial and operational results for the first quarter ended March 31, 2023 on Monday, May 15, 2023.

Rockwell Medical to Release First Quarter 2023 Financial Results on Monday, May 15, 2023

Lantheus Holdings

Viemed Healthcare

Here we discuss three medical instruments stocks, LNTH, RMTI and VMD, which are witnessing solid momentum in 2023. These stocks have the potential to continue their uptrend going forward.

3 Medical Product Stocks With Strong Potential to Gain in 2023

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will be exhibiting in booth #503 at the National Kidney Foundation Spring Clinical Meetings in Austin, TX on April 11-15, 2023.

Rockwell Medical to Exhibit at the National Kidney Foundation SCM23

Rockwell Medical (RMTI) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Here Is Why Bargain Hunters Would Love Fast-paced Mover Rockwell Medical (RMTI)

Rockwell Medical, Inc. (NASDAQ:RMTI ) Q4 2022 Earnings Conference Call March 30, 2023 8:00 AM ET Company Participants Heather Hunter - Senior Vice President and Chief Corporate Affairs Officer Mark Strobeck - President and Chief Executive Officer Tim Chole - Senior Vice President, Sales and Marketing Paul McGarry - Senior Vice President, Finance and Chief Accounting Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Operator Good morning, and welcome to Rockwell Medical's Fourth Quarter and Full-Year 2022 Results Conference Call and Webcast. Please note, this event is being recorded.

Rockwell Medical, Inc. (RMTI) Q4 2022 Earnings Call Transcript

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell achieved three consecutive quarters of improved financial performance, culminating in the highest full-year revenue to-date for the Company.

Rockwell Medical Announces Fourth Quarter and Full-Year 2022 Financial and Operational Results

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical is exhibiting in Booth #502 at DialysisTechConneXion40 in Las Vegas, NV from March 28-31, 2023.

Rockwell Medical to Showcase its Hemodialysis Concentrates Portfolio at DialysisTechConneXion40

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical has been certified as a Great Place to Work in 2023, the Company's inaugural year participating in the accreditation.

Rockwell Medical Named 'Great Place to Work'

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #ESKD--Rockwell Medical to Release Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 30, 2023.

Rockwell Medical to Release Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 30, 2023

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #endstagekidneydisease--Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, announced that the Company signed a three-year product purchase agreement with Concerto Renal Services ("Concerto"), the largest provider of dialysis in skilled nursing facilities in the United States.

Rockwell Medical and Concerto Renal Services Establish New Three-Year, Multi-Million Dollar Product Purchase Agreement

WIXOM, Mich.--( BUSINESS WIRE )--Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, announced that the Company signed a three-year, multi-million dollar per annum product purchase agreement with the largest non-profit dialysis provider in the United States. As part of the agreement, Rockwell Medical will be the preferred supplier of liquid and dry acid and bicarbonate concentrates to this non-profit dialysis provider's hemodialysis facilities located throughout the United States.

Rockwell Medical Signs Three-Year, Multi-Million Dollar Supply Agreement with Largest Non-Profit Dialysis Provider in the United States

WIXOM, Mich.--( BUSINESS WIRE )--Rockwell Medical, Inc. (“Rockwell” or the “Company”) (Nasdaq: RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, announced that the Company is adding new business within the Minnesota region. Rockwell started to supply these clinics with its hemodialysis concentrates products effective December 5, 2022, anticipates that all clinics will be onboarded by January 1, 2023, and expects to generate over one million dollars in revenue the first year.

Rockwell Medical Begins Selling its Hemodialysis Concentrates Products to New Clinics in Minnesota with its Largest Customer

Rockwell Medical, Inc. (NASDAQ:RMTI ) Q3 2022 Earnings Conference Call November 14, 2022 8:00 AM ET Company Participants Heather Hunter - SVP & Chief Affairs Officer Mark Strobeck - President, CEO & Director Paul McGarry - Senior Vice President, Finance and Chief Accounting Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald & Co. Raghuram Selvaraju - HC Wainwright & Co. Operator Good morning, and welcome to Rockwell Medical's Third Quarter 2022 Results Conference Call and Webcast. Please note, this event is being recorded.

Rockwell Medical, Inc. (RMTI) Q3 2022 Earnings Call Transcript

WIXOM, Mich.--( BUSINESS WIRE )--Rockwell Medical, Inc. (“Rockwell” or the “Company”) (Nasdaq: RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, today provided an update on its overall business strategy and announced its financial and operational results for the third quarter ended September 30, 2022.

News for Rockwell Medical Stock (RMTI)